BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loggi E, Gitto S, Galli S, Minichiello M, Conti F, Grandini E, Scuteri A, Vitale G, Di Donato R, Cursaro C. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. J Clin Virol. 2017;93:66-70. [PMID: 28654775 DOI: 10.1016/j.jcv.2017.05.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Abdelbary MS, Samir R, El-nahaas SM, Hosny Shahin RM, El-sayed M, Gaber Y, Tantawi O, Zayed NA, Yosry A. Hepatitis B reactivation following eradication of HCV with direct-acting antiviral drugs (DAAs) in a cohort of patients from different institutions in Egypt. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.04.020] [Reference Citation Analysis]
2 Hanif FM, Majid Z, Luck NH, Tasneem AA, Laeeq SM, Mubarak M. Revolution in the diagnosis and management of hepatitis C virus infection in current era. World J Hepatol 2022; 14(4): 647-669 [DOI: 10.4254/wjh.v14.i4.647] [Reference Citation Analysis]
3 Jiang XW, Ye JZ, Li YT, Li LJ. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J Gastroenterol 2018; 24(28): 3181-3191 [PMID: 30065564 DOI: 10.3748/wjg.v24.i28.3181] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
4 Mücke MM, Backus LI, Mücke VT, Coppola N, Preda CM, Yeh M, Tang LSY, Belperio PS, Wilson EM, Yu M, Zeuzem S, Herrmann E, Vermehren J. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 2018;3:172-80. [DOI: 10.1016/s2468-1253(18)30002-5] [Cited by in Crossref: 81] [Cited by in F6Publishing: 30] [Article Influence: 20.3] [Reference Citation Analysis]
5 El Kassas M, Shimakawa Y, Ali-Eldin Z, Funk AL, Wifi MN, Zaky S, El-Raey F, Esmat G, Fontanet A. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. Liver Int 2018;38:2159-69. [PMID: 29738637 DOI: 10.1111/liv.13874] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
6 Bath RM, Doering BE, Nailor MD, Goodlet KJ. Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review. Ann Pharmacother 2019;53:294-310. [PMID: 30203666 DOI: 10.1177/1060028018800501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Yahya G, Hashem Mohamed N, Pijuan J, Seleem NM, Mosbah R, Hess S, Abdelmoaty AA, Almeer R, Abdel-Daim MM, Shulaywih Alshaman H, Juraiby I, Metwally K, Storchova Z. Profiling the physiological pitfalls of anti-hepatitis C direct-acting agents in budding yeast. Microb Biotechnol 2021. [PMID: 34378349 DOI: 10.1111/1751-7915.13904] [Reference Citation Analysis]
8 Sarıgul F, Sayan M, User U, Oztoprak N. Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict Rules. Hepat Mon 2019;In Press. [DOI: 10.5812/hepatmon.62390] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Wu T, Kwok RM, Tran TT. Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues. Am J Gastroenterol 2017;112:1780-8. [PMID: 29087395 DOI: 10.1038/ajg.2017.397] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
10 Chang JJ, Mohtashemi N, Bhattacharya D. Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era. Curr HIV/AIDS Rep 2018;15:172-81. [PMID: 29572624 DOI: 10.1007/s11904-018-0379-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
11 Townshend-Bulson L, Roik E, Barbour Y, Bruden DJT, Homan CE, Espera HGF, Stevenson TJ, Hewitt AM, Rhodes W, Gove JE, Plotnik JN, Snowball MM, McGilvray J, Simons BC, Johnston JM, McMahon BJ. The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals. PLoS One 2021;16:e0260970. [PMID: 34855920 DOI: 10.1371/journal.pone.0260970] [Reference Citation Analysis]
12 Preda CM, Popescu CP, Baicus C, Constantinescu I, Oproiu A, Voiosu T, Diculescu M, Negreanu L, Gheorghe L, Sporea I, Trifan A, Ceausu E, Proca D, Manuc M. Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin. J Viral Hepat 2018;25:834-41. [PMID: 29397016 DOI: 10.1111/jvh.12872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Abdelaal R, Yanny B, El Kabany M. HBV/HCV Coinfection in the Era of HCV-DAAs. Clin Liver Dis 2019;23:463-72. [PMID: 31266620 DOI: 10.1016/j.cld.2019.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Gitto S, Cursaro C, Bartoli A, Margotti M, Andreone P. Hepatitis C: clinical management and debated issues. Minerva Med 2021;112:228-37. [PMID: 33319975 DOI: 10.23736/S0026-4806.20.07208-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Poola S, Sanaka S, Sewell K, Tillmann HL. Hepatitis B surface antibody titres and hepatitis B reactivation with direct-acting antiviral therapy for hepatitis C. J Viral Hepat 2021;28:373-82. [PMID: 33047433 DOI: 10.1111/jvh.13421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Mak LY, Seto WK, Lai CL, Yuen MF. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opin Drug Metab Toxicol 2018;14:483-91. [PMID: 29718748 DOI: 10.1080/17425255.2018.1472236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
17 Zarębska-Michaluk D, Flisiak R, Flisiak-Jackiewicz M. Management of hepatitis B and hepatitis C coinfection: an expert review. Expert Rev Anti Infect Ther 2020;18:1033-44. [PMID: 32579414 DOI: 10.1080/14787210.2020.1776112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yanny BT, Latt NL, Saab S, Han S, Choi G, Kramer J, Sahota AK. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. J Clin Gastroenterol 2018;52:908-12. [PMID: 29334502 DOI: 10.1097/MCG.0000000000000986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
19 Jaroszewicz J, Pawłowska M, Simon K, Zarębska-Michaluk D, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Janczewska E, Paluch K, Dybowska D, Buczyńska I, Czauż-Andrzejuk A, Berak H, Krygier R, Piasecki M, Dobracka B, Citko J, Piekarska A, Socha Ł, Deroń Z, Tronina O, Laurans Ł, Białkowska J, Tomasiewicz K, Halota W, Flisiak R. Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA. Expert Rev Anti Infect Ther 2020;18:1045-54. [PMID: 32538232 DOI: 10.1080/14787210.2020.1782189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]